Who is sponsoring NCT02812121?

NCT02812121 is sponsored by Sun Yat-sen University.

What condition does NCT02812121 study?

NCT02812121 studies Liver Failure.

What drugs are being tested in NCT02812121?

Interventions: umbilical cord blood mesenchymal stem cells.

What is the status of NCT02812121?

NCT02812121 is currently UNKNOWN.

Last reviewed 2016-06-21 · How we verify

Umbilical Cord Blood Derived Mesenchymal Stem Cells Infusion for HBV-Related Acute-on-Chronic Liver Failure: A Randomized Controlled Trial

NCT02812121 Phase 2 UNKNOWN

Hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) is a severe disease with high mortality. Our previous study have demonstrated that peripheral infusion of bone marrow-derived mesenchymal stromal cells (MSCs) weekly for 4 times is safe and improves 24 weeks survival rate of ACLF patients. In this study, we intend to assess the safety and efficacy of umbilical cord blood derived MSCs for HBV-related ACLF patients.

Details

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	UNKNOWN
Enrolment	261
Start date	2016-06
Completion	2018-06

Conditions

Liver Failure

Interventions

umbilical cord blood mesenchymal stem cells

Primary outcomes

The incidence of adverse reactions after umbilical cord blood derived mesenchymal stem cells (UC-MSC) infusions. — 52 weeks
The survival time of patients after UC-MSC infusions. — 52 weeks